Risk of liver decompensation with cumulative use of mitochondrial toxic nucleoside analogues in HIV/hepatitis C virus coinfection-Reference-Cited by-同舟云学术

Risk of liver decompensation with cumulative use of mitochondrial toxic nucleoside analogues in HIV/hepatitis C virus coinfection

Published:2017-07-19 Issue:10 Volume:26 Page:1172-1181
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiol Drug Saf

Author:

Lo Re Vincent¹²³^ORCID,Zeldow Bret²,Kallan Michael J.²,Tate Janet P.⁴⁵,Carbonari Dena M.²,Hennessy Sean²,Kostman Jay R.⁶,Lim Joseph K.⁴⁵,Goetz Matthew Bidwell⁷,Gross Robert¹²³,Justice Amy C.⁴⁵,Roy Jason A.²

Affiliation:

1. Department of Medicine, Perelman School of Medicine; University of Pennsylvania; Philadelphia PA USA

2. Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, and Center for Pharmacoepidemiology Research and Training, Perelman School of Medicine; University of Pennsylvania; Philadelphia PA USA

3. Medical Service, Corporal Michael J. Crescenz VA Medical Center; Philadelphia PA USA

4. VA Connecticut Healthcare System; West Haven CT USA

5. Yale University School of Medicine; New Haven CT USA

6. Philadelphia Field Initiating Group for HIV Trials; John Bell Health Center; Philadelphia PA USA

7. VA Greater Los Angeles Healthcare System and David Geffen School of Medicine; University of California Los Angeles; Los Angeles CA USA

Funder

Center for Pharmacoepidemiology Research and Training at the Perelman School of Medicine, University of Pennsylvania

Agency for Healthcare Research and Quality

National Institute on Alcohol Abuse and Alcoholism

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Reference53 articles.

1. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group;Sherman;Clin Infect Dis,2002

2. Factors associated with prevalent hepatitis C infection among HIV-infected women with no reported history of injection drug use: the Women's Interagency HIV Study (WIHS);Frederick;AIDS Patient Care STDS,2009

3. Hepatitis C prevalence among HIV-positive MSM in San Francisco: 2004 and 2008;Raymond;Sex Transm Dis,2011

4. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection;Qurishi;Lancet,2003

5. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy;Brau;J Hepatol,2006

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Causes and outcomes of hepatic fibrosis in persons living with HIV;Current Opinion in HIV and AIDS;2022-09-12

2. Do contemporary antiretrovirals increase the risk of end‐stage liver disease? Signals from patients starting therapy in the North American AIDS Cohort Collaboration on Research and Design;Pharmacoepidemiology and Drug Safety;2021-11-23

3. Polypharmacy-associated risk of hospitalisation among people ageing with and without HIV: an observational study;The Lancet Healthy Longevity;2021-10

4. Liver Fibrosis during Antiretroviral Treatment in HIV-Infected Individuals. Truth or Tale?;Cells;2021-05-15

5. A semiparametric modeling approach using Bayesian Additive Regression Trees with an application to evaluate heterogeneous treatment effects;The Annals of Applied Statistics;2019-09-01